Cagrilintide + Semaglutide

Description

The Cagrilintide + Semaglutide combination (also studied under the designation CagriSema) represents a dual-agonist research approach combining a long-acting amylin analog (Cagrilintide) with a GLP-1 receptor agonist (Semaglutide). This combination targets two distinct but complementary metabolic pathways: amylin receptor signaling for satiety and gastric emptying, and GLP-1 receptor activation for incretin-mediated glucose regulation and appetite suppression. Preclinical and clinical research has investigated the synergistic effects of co-administering these two peptides, with studies suggesting enhanced metabolic outcomes compared to either agent alone. The combination approach reflects growing interest in multi-receptor agonism strategies for metabolic research. Supplied as a lyophilized powder blend. For research use only.